Traditional Chinese medicine composition for treating rheumatoid arthritis osteoclast and application of traditional Chinese medicine composition

Abstract

The invention discloses a traditional Chinese medicine composition for treating rheumatoid arthritis osteolysis and application thereof. The traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 6 to 12 parts of rhizoma curculiginis (roasted with wine), 9 to 15 parts of herba epimedii, 6 to 12 parts of radix clematidis, 10 to 15 parts of radix angelicae sinensis, 9 to 15 parts of radix achyranthis bidentatae, 6 to 15 parts of fructus lycii and 2 to 10 parts of liquorice root. The traditional Chinese medicine composition has the effects of synergistically warming and invigorating kidney yang and strengthening muscles and bones, can reduce expression of inflammatory factors TNF-alpha, IL-6 and IL-1beta in plasma of mice with collagen-induced arthritis (CIA), reduces inflammatory cell infiltration in synovial tissues, remarkably reduces the number of osteoclasts and erosion progress, and is good in safety.

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicine, and in particular relates to a traditional Chinese medicine composition for treating rheumatoid arthritis bone destruction and application thereof. Background Art

[0002] Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic, symmetrical, and progressive polyarthritis. Its pathological features are abnormal proliferation of synovial tissue, inflammatory cell infiltration, and pannus formation, ultimately leading to progressive destruction of articular cartilage and bone (i.e., bone destruction), a major cause of disability. According to statistics, the global incidence of RA is approximately 0.5%-1%. The large number of patients in my country creates a heavy disease burden, severely impacting patients' quality of life and work ability.

[0003] Currently, the clinical treatment of RA is primarily based on Western medicine, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs, such as methotrexate and leflunomide), biologics (such as TNF-α inhibitors and IL-6 receptor antagonists), and small molecule targeted drugs (JAK inhibitors). These drugs have achieved certain efficacy in controlling inflammation, alleviating symptoms, and delaying joint structural damage. However, Western medicine treatment still faces many challenges: ① Side effects of long-term use: such as gastrointestinal reactions, hepatotoxicity, renal toxicity, bone marrow suppression, and increased risk of infection; ② Poor response or drug resistance in some patients: Some patients do not respond well to existing drugs or develop drug resistance; ③ High economic burden: Biologics and small molecule targeted drugs, in particular, are expensive, and long-term use carries a heavy economic burden; ④ Inadequate targeting of bone destruction: Although some biologics (such as anti-RANKL antibodies) can directly inhibit bone resorption, the targeting and effectiveness of existing mainstream treatment options in preventing or reversing the bone destruction process in RA still need to be improved, and many of them suffer from the aforementioned side effects.

[0004] In Traditional Chinese Medicine (TCM), RA falls under the category of "bi syndrome" or "wangbi syndrome." TCM believes that its onset is often due to liver and kidney deficiency, insufficient Qi and blood, and the combined effects of external pathogens such as wind, cold, dampness, and heat, leading to obstruction of the meridians and accumulation of phlegm and blood stasis. The development of Chinese patent medicines for RA has also made some progress. For example, Kunxian Capsule (main ingredients: Kunming Haitang, Epimedium, Lycium barbarum, and Cuscuta chinensis) is one of the Chinese patent medicines approved for the treatment of RA in China. Its main functions are to "tonify the kidneys, dredge the meridians, and dispel wind and dampness. It is primarily used to treat rheumatoid arthritis characterized by rheumatic arthritis and kidney deficiency." Kunxian Capsule has demonstrated certain anti-inflammatory and immunomodulatory effects in clinical practice. However, Kunming Haitang, the main ingredient in Kunxian Capsule, has potential reproductive toxicity and some hepatotoxicity, limiting its long-term safe use in certain populations (such as those of childbearing age and those with liver and kidney dysfunction). More importantly, the research and clinical focus of most existing anti-RA Chinese patent medicines, including Kunxian Capsules, are mainly focused on inhibiting inflammation, relieving symptoms such as joint swelling and pain, and morning stiffness. There is relatively insufficient targeted research on how to effectively intervene in and repair the core pathological changes of RA - joint bone destruction (bone erosion, joint space narrowing) - the mechanism of action is not clearly explained, and the clinical evidence chain is still incomplete.

[0005] Bone destruction is a key factor in RA disability, primarily mediated by overactive osteoclasts. Research indicates that the kidneys are responsible for bone and marrow production, and that kidney yang deficiency is a key intrinsic pathogenesis of RA bone destruction. Insufficient kidney yang weakens the body's ability to warm and promote bone function, leading to the accumulation of pathogenic qi (cold, dampness, phlegm, and blood stasis) that obstructs the bones and tendons. This not only causes pain and swelling but can also penetrate deep into the joints, eroding the bones and damaging the tendons. Therefore, warming and tonifying kidney yang, strengthening tendons and bones, and removing blood stasis and unblocking the meridians are key therapeutic approaches for preventing and treating bone destruction in RA. Summary of the Invention

[0006] The purpose of the present invention is to provide a Chinese medicine composition for inhibiting bone destruction in rheumatoid arthritis, so as to solve the problems of insufficient efficacy or safety risks of existing therapeutic drugs in inhibiting bone destruction in rheumatoid arthritis.

[0007] In some embodiments, a traditional Chinese medicine composition for treating bone destruction in rheumatoid arthritis of the present invention is composed of the following medicinal materials in parts by weight: 6-12 parts of Curculigo (fried with wine), 9-15 parts of Epimedium, 6-12 parts of Clematidis, 10-15 parts of Angelica, 9-15 parts of Achyranthes, 6-15 parts of Lycium barbarum and 2-10 parts of Licorice.

[0008] In some embodiments, a traditional Chinese medicine composition for treating bone destruction in rheumatoid arthritis of the present invention is composed of the following medicinal materials in parts by weight: 8-10 parts of Curculigo (fried with wine), 11-13 parts of Epimedium, 8-10 parts of Clematidis, 12-13 parts of Angelica, 11-13 parts of Achyranthes, 9-12 parts of Lycium barbarum and 4-8 parts of Licorice.

[0009] In some preferred embodiments, a traditional Chinese medicine composition for treating bone destruction in rheumatoid arthritis of the present invention is composed of the following medicinal materials in parts by weight: 8 parts of Curculigo (fried with wine), 11 parts of Epimedium, 8 parts of Clematidis, 12 parts of Angelica, 11 parts of Achyranthes, 9 parts of Lycium barbarum and 4 parts of Licorice.

[0010] In some preferred embodiments, a traditional Chinese medicine composition for treating bone destruction in rheumatoid arthritis of the present invention is composed of the following medicinal materials in parts by weight: 9 parts of Curculigo (fried with wine), 12 parts of Epimedium, 9 parts of Clematidis, 12 parts of Angelica, 12 parts of Achyranthes, 12 parts of Lycium barbarum and 6 parts of Licorice.

[0011] In some embodiments, the Chinese medicine composition for treating rheumatoid arthritis bone destruction of the present invention is prepared in the form of decoction, oral liquid, mixture, syrup, oral tablet, capsule, pill, granule or injection.

[0012] Preferably, the above-mentioned Chinese medicine composition of the present invention is in the form of a decoction.

[0013] In other embodiments, the present invention provides a method for preparing a decoction of the above-mentioned traditional Chinese medicine composition, comprising the following steps:

[0014] 1) Prepare the ingredients: weigh the Chinese herbal medicines in the prescription according to the amount;

[0015] 2) Soaking: Mix the weighed pieces of Chinese herbal medicine evenly, place them in a suitable decoction container, add water to cover the surface of the medicine by 2-3 cm, and soak for 30 minutes;

[0016] 3) Decoction: Heat the soaked herbs together with the soaking solution to a boil, maintaining a slight boil for the first decoction, which takes 45-60 minutes. After decoction is complete, filter while hot, collect the filtrate, and retain the residue.

[0017] 4) Add water to the medicinal residue from the previous step to cover the medicinal surface and heat directly to boiling, keep it in a slightly boiling state for the second decoction, the decoction time is 20-25 minutes, filter the medicinal liquid,

[0018] 5) The filtrates from steps 3) and 4) are combined and mixed to obtain the product.

[0019] The decoction of the Chinese medicine composition of the present invention is taken three times a day.

[0020] In some embodiments, the present invention provides use of the above-mentioned traditional Chinese medicine composition of the present invention in the preparation of a drug for treating bone destruction in rheumatoid arthritis.

[0021] Based on years of clinical practice and Traditional Chinese Medicine theory, the inventors have proposed a novel Chinese medicine composition to address the critical challenge of RA bone destruction. This formula, centered around warming and tonifying kidney yang, dispelling cold and dampness, and dredge meridians to relieve pain, features rigorous compatibility and addresses both the symptoms and the root cause. Curculigo orchioides, roasted with wine, serves as the main ingredient, leveraging its warming and unblocking properties to tonify the vital gate fire, strengthening bones and relieving atrophy. Herba Epimedii, combined with the main ingredient, warms kidney yang and dispels cold numbness. Together, these two herbs tonify the kidney and strengthen the Du meridian, directly addressing the root cause of kidney deficiency and bone atrophy. Angelica sinensis nourishes and invigorates blood circulation, tonifying the liver and moistening tendons and bones. Achyranthes bidentata guides the herb downward to the affected area, activating blood circulation and unblocking joints. Together, these two herbs resolve the stasis caused by chronic illness entering the meridians. Clematis chinensis dispels wind and dampness, dredges meridians and relieves pain, specifically targeting pathogenic factors stagnant in the meridians. Lycium barbarum nourishes yin and replenishes essence, counteracting its warming and drying properties and supporting the transformation of kidney essence into marrow and bone. Licorice balances the other ingredients, relieving urgency and relaxing tendons.

[0022] The following are the functions and effects of the main components of traditional Chinese medicine formulas:

[0023] Curculigo is pungent, hot, and toxic. It enters the kidney, liver, and spleen meridians. It tonifies kidney yang, strengthens tendons and bones, and dispels cold and dampness. It is used to treat impotence, cold semen, weak tendons and bones, cold pain in the waist and knees, and cold diarrhea caused by yang deficiency. Modern medical research indicates that the phenolic glycosides in Curculigo inhibit osteoclast formation, differentiation, and bone resorption, as well as have anti-inflammatory properties.

[0024] Epimedium is pungent, sweet, and warm in nature. It enters the liver and kidney meridians. It tonifies kidney yang, strengthens bones and muscles, and dispels rheumatism. It is used to treat kidney yang deficiency, impotence, spermatorrhea, weakness of bones and muscles, rheumatic pain, numbness, and cramps. Modern medical research indicates that its active ingredients, such as icariin, promote osteoblast proliferation, inhibit osteoclast function, and have anti-inflammatory effects.

[0025] Clematidis Radix has a pungent, salty, and warming nature. It enters the Bladder Meridian. It dispels rheumatism and dredges the meridians. It is used to treat rheumatic pain, numbness of the limbs, muscle spasms, and difficulty flexing and extending. Modern medical research indicates that Clematidis Radix and its active ingredient, magnolamine, have anti-inflammatory properties.

[0026] Angelica sinensis is sweet, pungent, and warm in nature. It enters the liver, heart, and spleen meridians. It nourishes and invigorates blood circulation, regulates menstruation and relieves pain, and moistens the intestines and promotes bowel movements. It is used for sallow complexion caused by blood deficiency, dizziness and palpitations, irregular menstruation, amenorrhea, dysmenorrhea, abdominal pain caused by cold and deficiency, rheumatic pain, injuries from falls, carbuncles, ulcers, and constipation caused by dry intestines. Modern medical research shows that the active ingredients in Angelica sinensis can inhibit osteoclast formation and bone resorption, and have anti-inflammatory effects.

[0027] Achyranthes bidentata (Achyranthes bidentata) has a bitter, sweet, sour, and neutral nature. It enters the Liver and Kidney meridians. It has the effects of removing blood stasis, tonifying the liver and kidneys, strengthening the tendons and bones, promoting urination and relieving stranguria, and guiding blood downward. It is used to treat amenorrhea, dysmenorrhea, soreness of the waist and knees, weakness of the tendons and bones, stranguria, edema, headache, dizziness, toothache, mouth ulcers, hematemesis, and epistaxis. Modern medical research shows that Achyranthes bidentata and its active ingredients have anti-inflammatory and osteoclast differentiation inhibitory effects.

[0028] Lycium barbarum fruit is sweet and neutral in nature. It enters the liver and kidney meridians. It nourishes the liver and kidneys, improves intelligence, and improves vision. It is used for consumptive diseases such as deficiency of essence, soreness of the waist and knees, dizziness, tinnitus, impotence, spermatorrhea, internal heat and thirst, blood deficiency, sallow complexion, and blurred vision. Modern medical research shows that Lycium barbarum polysaccharides can inhibit osteoclast proliferation, migration, and differentiation.

[0029] Licorice root (Glycyrrhiza uralensis) is sweet and neutral in nature. It enters the Heart, Lung, Spleen, and Stomach meridians. It tonifies the spleen and replenishes Qi, clears away heat and detoxifies, eliminates phlegm and relieves cough, relieves pain, and harmonizes various medicinal properties. It is used to treat spleen and stomach deficiency, fatigue, palpitations, shortness of breath, cough with sputum, acute pain in the abdomen and limbs, carbuncles, sores, and alleviates drug toxicity and potency. Modern medical research also shows that the active ingredients in licorice, such as liquiritin and glycyrrhizin, can inhibit osteoclast differentiation.

[0030] The advantages of the Chinese medicine composition of the present invention are:

[0031] ① Directly targeting the core pathogenesis of bone destruction: Wine-roasted Curculigo and Epimedium serve as the main herbs, synergistically warming and tonifying kidney yang, strengthening tendons and bones, and enhancing bone resistance to erosion from the root. Angelica sinensis and Achyranthes bidentata act as auxiliary herbs to promote blood circulation, remove blood stasis, and unclog the meridians. Together, they work with Clematidis to dispel rheumatic factors that obstruct tendons and bones, eliminating the pathological factors that cause bone destruction. Lycium barbarum nourishes yin and invigorates essence, assisting in regulating warming and dryness, while licorice harmonizes the medicinal properties, creating a formula that addresses both the symptoms and the root cause.

[0032] ② The present invention can reduce the expression of inflammatory factors TNF-α, IL-6, and IL-1β in the plasma of mice with collagen-induced arthritis (CIA). HE staining results showed that it can reduce inflammatory cell infiltration in synovial tissue; TRAP staining showed a significant decrease in the number of osteoclasts. Simultaneously, the present invention can also downregulate the expression of osteoclast differentiation-related proteins CTSK, MMP-9, and TRAP, thereby reducing the progression of bone erosion in joint imaging.

[0033] ③Safety considerations: The Kunming Crabapple, which has clear reproductive toxicity, is avoided in Kunxian Capsules. The formula is relatively safe and more suitable for long-term use to control the course of chronic disease and bone destruction. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 This is a bar graph showing the effect of the Chinese medicine composition of Example 5 on the plasma inflammatory factors TNF-α, IL-6 and IL-1β in mice with collagen-induced arthritis.

[0035] Figure 2 This is a HE staining image of the ankle joint of mice with collagen-induced arthritis using the traditional Chinese medicine composition of Example 5.

[0036] Figure 3 This is a TRAP staining image of the ankle joints of mice with collagen-induced arthritis treated with the traditional Chinese medicine composition of Example 5.

[0037] Figure 4This is a graph showing the effect of the Chinese medicine composition of Example 5 on osteoclast differentiation-related proteins CTSK, MMP-9 and TRAP in collagen-induced arthritis mice.

[0038] Figure 5 This is an X-ray image of the Chinese medicine composition of Example 5 on the ankle and toe joints of mice with collagen-induced arthritis. DETAILED DESCRIPTION

[0039] The following examples are provided to describe the present invention in more detail. However, the following examples are provided only to help further understand the present invention and are not intended to limit the present invention. Those skilled in the art will appreciate that any equivalent substitutions made to the present invention, or corresponding improvements, still fall within the scope of protection of the present invention.

[0040] Example 1 Chinese medicine composition

[0041] Prescription composition: 6 parts of Curculigo (fried with wine), 9 parts of Epimedium, 6 parts of Clematidis, 10 parts of Angelica, 9 parts of Achyranthes, 6 parts of Lycium barbarum, and 2 parts of Licorice (weight unit is g).

[0042] Example 2 Chinese medicine composition

[0043] Prescription composition: 8 parts of Curculigo (fried with wine), 11 parts of Epimedium, 8 parts of Clematidis, 12 parts of Angelica, 11 parts of Achyranthes, 9 parts of Lycium barbarum, and 4 parts of Licorice (weight unit is g).

[0044] Example 3 Chinese medicine composition

[0045] Prescription composition: 9 parts of Curculigo (fried with wine), 12 parts of Epimedium, 9 parts of Clematidis, 12 parts of Angelica, 12 parts of Achyranthes, 12 parts of Lycium barbarum, and 6 parts of Licorice (weight unit is g).

[0046] Comparative Example 1

[0047] This embodiment provides a Chinese medicine preparation drug pair, including the following raw materials in parts by weight according to the Chinese medicine composition: 9 parts of Curculigo (fried with wine) and 12 parts of Epimedium (weight unit is g).

[0048] The beneficial effects of the pharmaceutical composition of the present invention are illustrated below through specific pharmacodynamic study results.

[0049] Example 4 Preparation of a decoction of a Chinese medicine composition

[0050] Take the Chinese medicine composition of Example 3, which contains 9g of Curculigo (fried with wine), 12g of Epimedium, 9g of Clematidis, 12g of Angelica, 12g of Achyranthes, 12g of Lycium barbarum, and 6g of Licorice. All Chinese herbal medicine pieces were provided by Chongqing Municipal Hospital of Traditional Chinese Medicine. First, weigh each Chinese herbal medicine according to the prescription, add water to cover the surface of the medicine by 2-3cm, and soak for 30 minutes; decoct for 45 minutes, and collect the first decoction liquid. Add water and decoct again for 20 minutes, collect the second filtrate, mix it with the first filtrate, and concentrate it to 936g / L to obtain a decoction, which is used as the following therapeutic efficacy test drug and stored at -20°C for future use. Based on the conversion ratio of 0.0026:1 for a 20g mouse to a 70kg human, the high dose (H-XMJB) administered to the experimental animals was 9.36g / kg (equivalent to 1% of the clinical dose), and the low dose (L-XMJB) was 4.68g / kg.

[0051] Take the Chinese medicine composition of the prescription of comparative example 1, 9g of Curculigo (fried with wine) and 12g of Epimedium. All Chinese medicine pieces were provided by Chongqing Municipal Hospital of Traditional Chinese Medicine. First weigh each Chinese medicine in the prescription according to the amount, add water to cover the medicine surface by 2-3cm, and soak for 30min; decoct for 45min, and collect the first decoction liquid. Add water and decoct again for 20min, collect the second filtrate, mix it with the first filtrate, concentrate the filtrate over low heat to 273g / L to form a decoction, and store it at -20℃ for use (as the positive control drug for the following experiments, abbreviated as XMYD). According to the conversion relationship of 20g mice to 70kg people is 0.0026:1, the experimental animals were administered 2.73g / kg of (XMYD) as a comparative agent.

[0052] Example 5: Drug efficacy test

[0053] Experimental animals: 50 SPF-grade male DBA / 1 mice (6-7 weeks old) were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd. (Animal Certificate No.: SCXK(Beijing)2021-0006). Mice were housed in Chongqing Jinfeng Laboratory at a temperature of 20-24°C and a relative humidity of 50%-65%, with free access to food and water. The animal experimental procedures were approved by the Animal Experimentation Ethics Committee of Chongqing Hospital of Traditional Chinese Medicine (Approval No. 2023-DWSY-LX).

[0054] Modeling:

[0055] After 1 week of adaptive feeding, 50 DBA / 1 mice were randomly selected as a normal control group (NG). The remaining mice were treated with a booster immunization-induced arthritis mouse model developed by Chondrex. For the initial immunization, 0.1 mL of the modeling agent (bovine type II collagen: complete Freund's adjuvant (CFA) = 1:1) was injected subcutaneously approximately 0.5 cm from the base of the tail. This day was designated as day 1. A booster immunization was performed on day 21, with 0.05 mL of the modeling agent (bovine type II collagen: incomplete Freund's adjuvant (IFA) = 1:1) injected subcutaneously approximately 1.5 cm from the base of the tail. On day 28, mice with an arthritis index (AI) score ≥ 4 were selected to be considered a successful CIA model. The mice were randomly divided into a model control group (MG), a positive control group (XMYD), which was orally administered with the positive control decoction of Example 4, and a low-dose test drug group (L-XMJB) and a high-dose test drug group (H-XMJB), which were orally administered with the therapeutic effect test drug decoction of Example 4. Each group had 8 mice, and the drugs were administered continuously for 28 days.

[0056] Detection indicators

[0057] After 28 days of administration, the mice were killed, and the levels of TNF-α, IL-1β, and IL-6 in the mouse plasma were detected by ELISA. The morphological changes of ankle joint tissue were analyzed by HE staining. The growth of osteoclasts was observed by TRAP staining. The expression of osteoclast differentiation-related proteins CTSK, MMP-9, and TRAP protein was detected by immunohistochemistry. X-rays of the paws were also taken.

[0058] Statistical processing methods

[0059] IBM SPSS Statistics 21.0 software was used for data statistical analysis. If the data were normally distributed and had homogeneous variance, one-way analysis of variance (ANOVA) was used, and LSD analysis was used for comparison between groups. If the data were not normally distributed or had heterogeneous variance, non-parametric tests were used. Figure 1-4 .

[0060] Figure 1 The results showed that compared with NG, the expression levels of TNF-α, IL-1β, and IL-6 in the plasma of MG mice were significantly increased (P<0.01). Compared with MG, XMYD significantly reduced the expression level of TNF-α (P<0.05), while L-XMJB and H-XMJB significantly reduced the expression levels of TNF-α, IL-1β, and IL-6 in the plasma (P<0.01 or P<0.05).

[0061] Figure 2Results showed that in the NG group, ankle joint tissue staining was uniform, the articular cartilage surface was smooth, the chondrocyte and osteocyte morphology and structure were normal, the tidemark structure was clear, and no significant synovial hyperplasia or inflammatory cell infiltration was observed on either side. In the MG group, joint tissue showed multiple necrosed and lysed chondrocytes and osteocytes, replaced by proliferating connective tissue, with minimal pannus formation. Synovial hyperplasia was observed on both sides, with punctate lymphocytic infiltration and a small amount of exudate visible in the joint cavity. Compared with MG, XMYD, L-XMJB, and H-XMJB all reduced synovial tissue hyperplasia, inflammatory cell infiltration, and articular cartilage destruction to some extent, with H-XMJB showing a more pronounced improvement.

[0062] Figure 3 The results showed that compared with NG, the number of osteoclasts in the ankle joints of MG mice was significantly increased; compared with MG, XMYD reduced the number of osteoclasts, and the number of osteoclasts in L-XMJB and H-XMJB decreased significantly with increasing dosage.

[0063] Figure 4 The results showed that compared with NG, the expression of CTSK, MMP-9 and TRAP proteins in MG was significantly increased; compared with MG, the expression of CTSK, MMP-9 and TRAP proteins in L-XMJB and H-XMJB was significantly decreased.

[0064] Figure 5 The results showed that the articular surfaces of the ankle and finger joints of NG mice were relatively smooth, the knee joint space was normal, and there was no osteophyte formation or bony hyperplasia. Compared with NG mice, MG mice showed osteophyte hyperplasia at the joint margins, a noticeably roughened articular surface, and a significantly narrowed joint space, accompanied by reactive subchondral bone hyperplasia. XMYD, L-XMJB, and H-XMJB administration all showed varying degrees of improvement, with the H-XMJB group showing the most significant improvement.

[0065] The above embodiments are merely representative, and any simple replacements and modifications based on the spirit of the present invention fall within the scope of the present invention.

Claims

1. A Chinese medicine composition for treating rheumatoid arthritis bone destruction, comprising the following medicinal materials in parts by weight: 6-12 parts of Curculigo (fried with wine), 9-15 parts of Epimedium, 6-12 parts of Clematidis, 10-15 parts of Chinese Angelica, 9-15 parts of Achyranthes, 6-15 parts of Lycium barbarum and 2-10 parts of Licorice.

2. The Chinese medicine composition according to claim 1, comprising the following medicinal materials in parts by weight: 8-10 parts of Curculigo (fried with wine), 11-13 parts of Epimedium, 8-10 parts of Clematidis, 12-13 parts of Angelica, 11-13 parts of Achyranthes, 9-12 parts of Lycium barbarum and 4-8 parts of Licorice.

3. The Chinese medicine composition according to claim 1, comprising the following medicinal materials in parts by weight: Curculigo (fried with wine) 8 parts, Epimedium 11 parts, Clematidis 8 parts, Chinese Angelica 12 parts, Achyranthes 11 parts, Fructus Lycii 9 parts and Radix Glycyrrhizae 4 parts.

4. The Chinese medicine composition according to claim 1, comprising the following medicinal materials in parts by weight: 9 parts of Curculigo (fried with wine), 12 parts of Epimedium, 9 parts of Clematidis, 12 parts of Angelica, 12 parts of Achyranthes, 12 parts of Lycium barbarum and 6 parts of Licorice.

5. The Chinese medicine composition according to any one of claims 1 to 4, wherein the preparation comprises decoction, oral liquid, mixture, syrup, oral tablet, capsule, pill, granule or injection. The Chinese medicine composition according to claim 5 , wherein the preparation is in the form of a decoction.

7. A method for preparing the decoction of claim 6, comprising the following steps: 1) Prepare the ingredients: weigh the Chinese herbal medicines in the prescription according to the amount; 2) Soaking: Mix the weighed pieces of Chinese herbal medicine evenly, place them in a suitable decoction container, add water to cover the surface of the medicine by 2-3 cm, and soak for 30 minutes; 3) Decoction: Heat the soaked herbs together with the soaking solution to a boil, maintaining a slight boil for the first decoction, which takes 45-60 minutes. After decoction is complete, filter while hot, collect the filtrate, and retain the residue. 4) Add water to the medicinal residue from the previous step to cover the medicinal surface and heat directly to boiling, keep it in a slightly boiling state for the second decoction, the decoction time is 20-25 minutes, filter the medicinal liquid, 5) The filtrates from steps 3) and 4) are combined and mixed to obtain the product.

8. Use of the traditional Chinese medicine composition according to any one of claims 1 to 4 in the preparation of a medicament for treating bone destruction in rheumatoid arthritis.

Images